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Abstract: A new insulin and nutrition control method for tight glycaemic control in 
critical care is presented from concept to clinical trials to clinical practice change. The 
primary results show that the method can provide very tight glycaemic control in critical 
care for a very critically ill cohort. More specifically, the final clinical practice change 
protocol provided 2100 hours of control with average blood glucose of 5.8 +/- 0.9 
mmol/L for an initial 10 patient pilot study. It also used less insulin, while providing the 
same or greater nutritional input, as compared to retrospective hospital control for a 
relatively very critically ill cohort with high insulin resistance. Copyright © 2006 IFAC 
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1. INTRODUCTION 
 
Hyperglycaemia is prevalent in critical care, and 
worsens outcomes, increasing the risk of severe 
infection, myocardial infarction, neuropathy, and 
multiple organ failure (Krinsley, 2003; Van den 
Berghe et al., 2001). Tight glucose control can 
reduce mortality by up to 45%. However, insulin-
mediated control, is severely challenged in critical 
care by very high effective insulin resistance 
(McCowen et al., 2001; Mizock, 2001). 
Glycaemic reductions are thus limited by insulin 
effect saturation at high concentrations (Prigeon et 
al., 1996). Next, high glucose content nutritional 
support exacerbates hyperglycaemia (Weissman, 
1999) and studies with lower glucose nutrition 
alone saw large reductions in glucose levels 
(Patino et al., 1999).  
 
 
2. MODELS and METHODS 
 
This research presents the development of an 
insulin nutrition method for tight glycaemic 
control in critical care. First, a virtual cohort is 
used to develop the method in simulation. Second, 
the methods are tested in limited proof of concept 
clinical trials. Finally, a paper-based method that 
mimics the computerised controller is introduced 
as a clinical practice change for long-term testing 
to validate the overall concept. 
 
2.1 Control Model 
 
Chase et al (2005a) used a system model that that 
included insulin utilisation, losses and saturation. 
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where G(t) [mmol/L] is the plasma glucose above 
an equilibrium level, GE [mmol/L]. I(t) [mmol/L] 
is plasma insulin concentration resulting from 
exogenous insulin input, uex(t) [mU/min]. Q(t) 
[mU/L] is interstitial insulin concentration and k 
[1/min] accounts for the effective life of insulin in 
the system. Patient endogenous glucose clearance 
and insulin sensitivity are pG [1/min] and SI 
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[L/(mU.min)], respectively. V [L] is the insulin 
distribution volume and n [1/min] is the constant 
first order decay rate for insulin from plasma.  
Total plasma glucose input is denoted P(t) 
[mmol/(L.min)]. kpr is the rise rate of rate of 
plasma glucose input from enterally administered 
feed [1/min]. kpd  is the decay rate of rate of 
glucose input into plasma from enterally 
administered feed [1/min]. iP , 1+iP  are stepwise 
consecutive enteral glucose feed rates 
[mmol/L.min]. Michaelis-Menten functions model 
saturation, with αI [L/mU] for the saturation of 
plasma insulin disappearance, and αG [L/mU] for 
the saturation of insulin-dependent glucose 
clearance. In this research, k, n, αG, αI and V are 
identified from generic population values. Details 
of the model, its development, and control analyses 
presented for it and similar models models can be 
found in (Chase, et al., 2005a).  
 
2.2 Control Method 
 
In this study, non-steady stepwise enteral glucose 
fluxes are employed for control and modelled 
using the 2-compartment model in Eqs. (4-5). The 
exponential rates for total glucose rate of 
appearance (GRa) rise (kpr) and decay (kpd) model 
the effect of transient net hepatic glucose output 
and glucose disposal. Impaired splanchnic and 
peripheral glucose uptake imply a slow decay rate 
in total GRa following nutritional feed reduction 
(Kiwanuka et al., 2001). Conversely, the rate of 
peripheral appearance of oral glucose is 
approximately equal to the intestinal absorption 
rate, implying a rapid rise following a nutritional 
increase (Radziuk et al., 1978).  Thus, kpr and kpd 
are set to 0.0347min-1 and 0.0068min-1 (half-lives 
of 20 and 100mins) to reflect this data.   
 
The controller targets 10-15% hourly glycaemic 
reduction to 5mmol/L using a combination of 
insulin bolus, infusion and/or feed rate change. The 
goal is blood glucose in the 4-6mmol/L band. 
Thus, insulin sensitivity, SI, is fitted from the prior 
hours’ data before each intervention (Hann et al., 
2005) and endogenous clearance, pG, is set to 
0.01min-1, a value found  to be insensitive across 
this type of cohort (Hann et al., 2005). Finally, the 
required combination of insulin bolus, insulin 
infusion rate and/or nutritional feed rate to achieve 
the hourly target glucose is determined iteratively 
using the updated SI, value and Eqs. (1)-(5).   
 
2.3 Virtual Cohort and Simulated Trials 
 
The patient cohort includes 17 patients from a 201 
patient data audit plus 2 patients from a 
hyperglycaemia control clinical trial (Chase et al., 
2005b). It represents a general cross-section of 
ICU population, in medical subgroup, APACHE II 
score, age, sex and mortality. Each record has 
glucose measurements every 3h or less. The 
average length is 3.9 days (range: 1.4-18.8). The 
cohort details are in Table 1. Ethical consent was 
granted by the Canterbury Ethics Committee.   
 
Virtual trials use the retrospective fitted patient 
profiles of SI and pG, to simulate physiological 
patient response. It assumes these parameters are 
independent of the control inputs administered, 
creating a virtual patient response for any glucose 
or insulin inputs. Normally distributed error of 
±7% is added to measured glucose values to 
include typical glucometer measurement error.  
 
Table 1: Long-Term Virtual Trial Patient Cohort 
Patient 
number
Medical 
subgroup
Apache II 
score Age Sex Mortality Diabetes
1 Sepsis 17 56 M Type 2
2 Sepsis 24 64 M
24 Other medical 25 47 M Y Type 1
87 Other medical 26 62 F
130 Trauma 11 21 M Type 1
229 Cardiac 15 73 F
289 Cardiac 18 70 M
468 General surgical 32 76 M
484 Other medical 34 30 F
486 General surgical 22 76 F Type 2
519 General surgical 29 69 M Type 2
554 Other medical 26 20 F Type 1
666 Cardiac 8 44 F Type 2
847 Other medical 17 67 F
1016 General surgical 20 37 F Type 2
1025 Pulmonary 36 48 M Type 2
1090 General surgical Unknown 37 F
1099 Pulmonary Unknown 24 M Y
1125 Other medical Unknown 72 F Y  
 
Each patient is tested using the control method. 
Results are compared to retrospective hospital data 
and an insulin-only control protocol (Chase et al., 
2005a).  The control method uses three basic steps: 
 
• Measure glucose every 30 minutes 
• Every hour fit SI based on prior hours data 
• Determine the insulin and nutritional changes 
to meet target reduction 
 
Frequent measurement ensures tight control and 
safety. Hence, these trials are used for proof of 
concept testing of the insulin plus nutrition control 
concept. Less frequent measurement would be 
required for long-term clinical care. 
 
2.4 Clinical Trials Method 
 
The methods developed virtually are tested in short 
10-hour proof-of-concept trials and one 24-hour 
trial. Inclusion criteria: in situ enteral feeding tube; 
random glucose level >8mmol/L; age >16 years; 
and an in situ cannula. Exclusion criteria: delayed 
gastric emptying; moribund; neuromuscular 
blockade; and morbid obesity (BMI>35kgm-2). 
 
Patients are fed enterally with RESOURCE™ 
Diabetic (Novartis Medical Nutrition, USA) up to 
700kcal/day of glucose using a Ross Products 
Patrol Enteral Pump (Abbott Laboratories, Abbott 
Park, Illinois, U.S.A.). Actrapid™ insulin (Novo 
Nordisk, Bagsvaerd, Denmark) is infused with a 
3500 syringe pump (Graseby Medical Limited, 
Colonial Way, Herts, UK). Ethical approval was 
obtained from the Canterbury Ethics Committee.   
 
The overall trial protocol is shown in Figure 1. 
During the 2-hour pre-trial period, the insulin 
     
infusion is kept constant to estimate the onboard 
insulin level in steady state. The blood glucose 
level at 0900h is taken as the equilibrium blood 
glucose, GE. At 0900h, feed rate is decreased by 
30-40% depending on current glucose level and 
feed rate as an initial challenge. Hourly glucose 
targets are set for a 10-15% reduction to a 
5mmol/L minimum. Insulin sensitivity, SI, is re-
evaluated every hour using the prior hours’ data. 
The controller prescribes insulin bolus size, insulin 
infusion rate, and feed rate to achieve the target.   
 
 
 
 
 
 
 
 
Fig.1: Clinical Trial Procedure 
 
Note that glucose is only measured hourly for the 
24-hour trial. This trial tests the ability of the 
controller to use less frequent measurements as a 
final step towards clinical, long-term testing. 
 
Insulin is limited to 6U/hr to minimise saturation 
and saturated, ineffective insulin is limited to 
30mU/L. The minimum feed rate is 280kcal/day of 
glucose or 40% of maximum for a total caloric 
intake of 778kcal/day (Novartis, 2005). This level 
exceeds the level found to avoid increased risk of 
bloodstream infections (Rubinson et al., 2004). 
 
2.5 Clinical Trials Cohort 
 
The clinical trial patient cohort (n = 8) represents a 
heterogeneous cross-section in age and sex, as 
shown in Table 2. The median APACHE II score 
is 23 with inter-quartile range [19, 25]. The mean 
age is 64.8 ± 7.8 years. 
 
Table 2: Clinical Trial Patient Cohort 
 
2.6 Long-term Testing – The SPRINT Protocol 
 
The clinical methods are developed and tested, 
first virtually and then in short proof of concept 
case studies. The final step is long-term clinical 
testing of this nutrition and insulin control 
approach. However, the measurement frequency 
must be reduced to 1-2 hourly for clinical ease of 
use. In addition, the methods must be removed 
from a computer and made paper based for easy 
uptake by clinical staff. 
 
The SPRINT (Specialised Relative Insulin 
Nutrition Tables) protocol is designed to nearly 
exactly mimic the computerised trial protocol, as 
an easy-to-use equivalent. It consists of two wheels 
dedicated to enteral nutrition and insulin bolus 
administration, as shown in Figure 2. Instructions 
are printed on the wheels and hourly blood glucose 
measurements are used to determine the next 
hour’s intervention.  
 
The instructions on the “Feed Wheel” are used to 
determine the rate of feed as a percentage of the 
patient’s clinically determined goal feed. The 
result is based on the previous hour’s feed level, 
the current blood glucose concentration and 
whether blood glucose is rising or falling. The 
percentage goal feed is converted into an absolute 
feed rate (in ml/hr) using a patient-specific 
conversion sticker. The “Insulin Wheel” is then 
used to determine the insulin bolus size based on 
the previous insulin bolus size, the current blood 
glucose level and whether the blood glucose has 
decreased by more than 1.5mmol/L. The method is 
effectively fully automated once clinical staff take 
the hourly glucose measurement. 
 
 
 
Fig.2: SPRINT feed and insulin wheels. 
Hourly blood glucose measurements are used to 
ensure tight control. Two-hourly measurements are 
used when the patient is stable, defined as 3 
consecutive measurements in the 4-6 mmol/L 
band. For two-hourly measurements, the feed rate 
is maintained and the same insulin bolus 
administered on the hour between measurements. 
Two-hourly measurements are continued until the 
patient leaves the 4-6 mmol/L band. SPRINT is 
stopped when the patient is stable, and 
normoglycaemic, defined as 6 or more hours in the 
4-6.1mmol/L band, with over 80% of goal feed 
rate and a maximum of 2U per hour of insulin. 
Finally, insulin is always administered via bolus 
for patient safety, avoiding infusions being left on.  
Patient 
number
Medical 
subgroup
APACHE II 
score
APACHE II 
ROD (%) APACHE III SAPS II
SAPS II 
ROD (%) Age Sex Mortality Diabetes
1 Sepsis 17 14.3 40 15 2 56 M N Type 2
2 Sepsis 24 49.7 59 35 16.7 64 M N
3 Pulmonary 31 73.3 85 45 34.8 60 M N
4 Sepsis 26 59.7 91 62 71.9 75 F N
5 Sepsis 21 33.2 58 34 15.3 73 M N Type 2
6 Other medical 17 14.3 44 44 32.6 57 M N
7 General surgical 23 62.3 84 57 61.9 73 F N Type 2
8 Other medical 60 M NNot available
HOURS 0 1 2 3 4 5 6 7 8 9 10
MINUTES 0 60 120 180 240 300 360 420 480 540
On the hour every hour: 
1.) Insulin sensitivity fitted
2.) Glucose target revised (if required) 
3.) Control input determined 
4.) Glucose target revised (if required) 
Feed reduction of 30-40% to start trial with 15 or 30 min measurement for first hour
30 min measurement interval 
     
The specific wheel layout resulted from extensive 
consultation. ICU staff were proficient in minutes 
and reported the system as very easy to use. A 
nursing survey reported that 25 of 27 respondents 
viewed the wheels as satisfactory or better, with 13 
rating it very good or higher. The covered wheel 
reduces table complexity, which reduces error.  
 
3. RESULTS and DISCUSSION 
 
3.1 Virtual Trial Results 
 
Figure 3 shows Patient 87 from retrospective 
hospital data, the insulin-only protocol (Chase et 
al., 2005a), and the variable feed and insulin 
protocol developed. Tight control in the 4-
6mmol/L desired band is clear with the variable 
nutrition protocol compared to the other protocols. 
The total insulin administered by the variable 
nutrition protocol is 38.5% less than the insulin-
only protocol (410.5U versus 667.0U). From the 
retrospective data, the total insulin infused was 
248.0U, indicating another source of poor control. 
Time spent in the desired 4-6mol/L band was 89% 
versus 21.8% for the insulin-only protocol and 
10.7% for hospital control. Finally, the results are 
achieved with total enteral glucose administered 
identical to the retrospective patient data (1284g 
versus 1286g). 
 
 
Fig.3: Patient 87 Virtual Trial Results 
 
A summary of the results for all patients is shown 
in Table 3. The variable nutrition and insulin 
controller increased the time spent in the 4-
6mmol/L band by 240% compared to the insulin-
only protocol and 312% versus the retrospective 
data. Time above 6mmol/L is reduced by 231% 
and 237%. No hypoglycaemic events occurred for 
any virtual trial protocols. Figure 4 summarises 
these results plotting percentage time in the 4-
6mmol/L band versus log mean fitted SI.   
 
Figure 4 shows that percentage time-in-band and 
mean blood glucose level decrease for all protocols 
with decreasing insulin sensitivity. With insulin 
alone, performance is highly dependent on the 
patients’ effective insulin resistance (R=0.90, 
p<0.001) due to saturation limitations (Chase et 
al., 2005a). The variable feed rate and insulin 
protocol provided tighter blood glucose control 
across the range of observed insulin sensitivities 
with significantly higher time-in-band (R=0.57, 
p<0.02). The insulin-only protocol only reached 
similar levels only at high insulin sensitivities, and 
with significantly more administered insulin. For 
hospital control, greater variation in blood glucose 
control was recorded, as expected (R=0.49, 
p<0.04), and showed tighter control than the 
insulin-only protocol only at low insulin 
sensitivities, where clinically selected feed 
reductions have affected the comparison. 
 
Table 3: Blood Glucose Summary – Virtual Trials 
Variable 
feed and 
insulin
Constant 
feed-rate, 
variable 
insulin
Hospital 
sliding-
scale
Variable 
feed and 
insulin
Constant 
feed-rate, 
variable 
insulin
Hospital 
sliding-
scale
1 6.0 12.1 9.3 66.8 1.6 10.2
2 5.9 9.8 7.8 78.4 0.9 3.6
24 6.6 12.4 12.2 80.1 0.0 0.0
87 5.4 8.4 8.8 89.1 21.8 10.7
130 7.0 13.2 11.2 60.1 0.0 10.3
229 5.4 7.7 7.5 84.6 30.2 15.5
289 5.3 5.5 6.8 80.8 79.8 13.2
468 8.5 10.4 7.4 43.4 0.0 18.5
484 7.5 12.3 11.5 70.0 0.0 0.0
486 6.5 9.4 8.9 60.7 10.6 12.0
519 5.6 7.8 6.3 78.6 51.4 33.9
554 6.0 7.6 6.9 66.5 36.1 20.9
666 7.2 12.4 5.3 35.7 0.0 74.9
847 6.2 6.2 7.3 75.5 75.7 21.7
1016 7.5 9.4 7.2 24.7 0.0 10.7
1025 6.4 7.9 8.0 59.5 41.3 21.0
1090 5.2 5.3 3.9 84.4 82.6 46.8
1099 5.3 5.5 6.5 88.6 82.4 35.8
1125 5.9 7.3 5.4 61.0 21.8 51.8
6.3 9.0 7.8 67.8 28.2 21.7
0.9 2.6 2.2 17.9 31.8 19.3
3.3 7.9 8.3 64.4 82.6 74.9
Percentage of time in 4-6mmol/L 
band (%)Mean Blood Glucose
Controller 
Type
Range
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Fig.4: Mean Insulin Sensitivity, SI, versus Time in 
the 4-6mmol/L Band 
 
In summary, these results all indicate the 
effectiveness of using nutrition as an added control 
input. In particular, high APACHE II score, very 
critically ill patients are generally highly insulin 
resistant. Thus, this added control path may 
represent the only means to maintain euglycaemia, 
as well as one that is not saturable as is the insulin 
path. 
 
3.2 Clinical Trial Results 
 
The main goal of the clinical trials was to prove 
the insulin and nutrition control concept by 
illustrating the potential for tight control. Tight 
control is shown by accurately reducing glucose 
Hospital Control 
Insulin Only (x) 
Hospital Control (▼) 
Insulin + Variable Nutrition (+) 
0 1000 2000 3000 4000 5000 6000 7000 8000 9000
2
4
6
8
10
12
14
16
18
Time (mins)
Bl
oo
d 
gl
uc
os
e 
co
nc
en
tra
tio
n 
(m
m
ol
/L
)
Insulin only
Variable feed
Hospital control
     
levels to pre-set target values. Hence, the target 
error is the main performance criteria for 
evaluation.  
 
The mean target error for all trials is 9.3% 
(0.52mmol/L), absolute range [0, 2.9] mmol/L, and 
41.9% of targets are achieved within ±5% with a 
mean target error of 2.6% (0.15mmol/L). Mean 
target error for errors >5% is 14.3% (0.79mmol/L). 
Out of 86 targets, only seven had errors >20%, so 
that 90.7% of all measurements are within ±20% 
of targets. More specifically almost 90% of target 
errors are explainable by measurement errors 
(Weitgasser et al., 1999). Outliers are attributed to 
significant and rapid changes in patient condition 
observed, such as atrial fibrillation. Model 
prediction errors at a 60min glucose measurement 
frequency (Trial 8) were not statistically 
discernible from the other trials. 
 
Figure 5 presents a bootstrapped linear regression 
model applied to the achieved and target glucose 
values using 6000 bootstrap samples. Also shown 
are the non-parametric 95% confidence intervals 
(CI) for the prediction of achieved glucose values 
for a given target. A correlation coefficient 
between 0.7695 and 0.8983 can be stated with 95% 
confidence. 
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Fig.5: Target Error Summary 
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Fig.6: Patient 2 Clinical Trial Progression 
 
Finally, Figure 6 shows a typical trial result for 
Patient 2. This trial highlights a common difficulty 
in critical care glycaemic control, the highly 
dynamic patient with rapidly evolving condition. 
The glucose measurement at 150mins was on 
course for the 5mmol/L target at 180mins. 
However, the recorded measurement at 180mins 
was 8.5mmol/L. The patient experienced atrial 
fibrillation at approximately 200mins, indicating 
that the change may have been due to adrenergic 
surge preceding the cardiac event. From that point, 
effective insulin resistance increased, requiring 
greater insulin input and feed rate reductions 
compared to the initial 60-120mins. The controller 
adapted to this not uncommon event, tracking the 
glucose measurements accurately within the next 
hour and the 300min target with 5.1% error. 
 
3.3 SPRINT Results 
 
The SPRINT protocol was implemented as a 
clinical practice change in the Christchurch 
Hospital ICU. The entry requirement was 2 
successive random glucose measurements over 8 
mmol/L. this limit ensures only the relatively more 
critically ill, and thus potentially more insulin 
resistant, patients are considered.  
 
An initial pilot study of 10 patients was performed 
to test SPRINT over long term clinical care. The 
cohort had an average age of 54 (range: 44-80), 
average APACHE II score of 23 (range: 11-37) 
and an average APACHE III score of 70 (range: 
34-108). There were 6 males and 4 females.  
 
The total controlled time is 2103 hours with 1579 
measurements indicating that 49.8% of the 
controlled time was on 2-hourly measurement as 
the patients were glycaemically stable. The 
average length of control for each patient was 210 
hours (8.75 days), also indicating a significantly 
critically ill cohort. 
 
The overall control results can be summarised: 
 
• Average Blood Glucose = 5.8 +/- 0.9 mmol/L 
• Average Insulin = 2.5 U/hour 
• Average Feed Rate = 64% (1279 kcal/day) 
• Time Feed Rate > 50% of goal feed = 70% 
 
However, more relevant performance is time in 
glycaemic band and any hypoglycaemic events. 
The primary bands are the 4.-6.1 mmol/L band 
defined by van den Berghe et al and the 4-7.75 
mmol/L band defined by Krinsley. More 
importantly, these bands are associated with 
reductions in mortality of 45% and 20-30% 
respectively, as well as significant reductions in 
other negative clinical outcomes. The overall 
glycaemic performance is thus summarised: 
 
• Time in the 4-6.1 mmol/L band = 64% 
• Time in the 4-7.0 mmol/L band =  89% 
• Time in the 4-7.75 mmol/L band =  97% 
• Number measurements < 4 mmol/L = 23 (1.5%) 
• Number Measurements < 3 mmol/L = 0 
• Minimum Blood Glucose = 3.2 mmol/L 
     
 
Thus, the results indicate that SPRINT provided 
very tight glycaemic regulation. The values for 
time in the glycaemic bands from the landmark 
studies on hyperglycaemia and mortality are also 
very high. This latter result indicates that 
glycaemic levels were not only tightly controlled 
on average, but that their variation was also very 
limited. This result is backed up by the narrow 0.9 
mmol/L standard deviation. Overall, the results 
indicate that modulating nutrition and insulin, in 
combination with frequent measurement, can 
provide very tight control for a very critically ill 
cohort. 
 
 
4. CONCLUSIONS 
 
This paper has presented the development, from 
concept to clinical practice change, of a nutrition 
plus insulin control methodology for maintaining 
euglycaemia in critical care. The methods are 
developed from a model-based virtual study to 
proof of concept clinical trials using a model based 
controller. The control method is then made paper 
based through a system that effectively mimics the 
model-based control methods, and implemented as 
a clinical practice change. Thus, the overall 
methodology of using retrospective data through to 
clinical change is also presented as an approach to 
developing this type of model-based control 
therapy. 
 
The overall results indicate that modulating 
nutrition and insulin is an effective approach to 
controlling hyperglycaemia in critical care. In 
particular, the more critically ill cohorts with 
higher APACHE II scores are typically more 
insulin resistant and this path may offer the only 
approach to lowering glucose levels to within a 
desired level or band. Also apparent in the need for 
higher measurement frequency to ensure that 
dynamic patients are well monitored and that 
inappropriate interventions of nutrition or insulin 
are not maintained when patient condition evolves 
significantly. 
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